Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Transcainide(R 54718), a new lidocaine analog, is an orally active antiarrhythmic agent.Transcainide blocks the open state of BTX-activated sodium channels in bovine heart and rat skeletal muscle.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 268.00 | |
5 mg | In stock | $ 663.00 | |
10 mg | In stock | $ 943.00 | |
25 mg | In stock | $ 1,390.00 | |
50 mg | In stock | $ 1,880.00 | |
100 mg | In stock | $ 2,560.00 |
Description | Transcainide(R 54718), a new lidocaine analog, is an orally active antiarrhythmic agent.Transcainide blocks the open state of BTX-activated sodium channels in bovine heart and rat skeletal muscle. |
In vitro |
Transcainide (IC50=0.3 μM) inhibited equilibrium [3H]batrachotoxinin binding to sodium channels present on freshly isolated rat cardiac myocytes. Scatchard analysis of [3H]batrachotoxinin binding showed that Transcainide both reduced maximal binding and altered the KD for [3H]batrachotoxinin binding, indicating noncompetitive, allosteric inhibition. Inhibition by Transcainide of [3H]batrachotoxinin binding was reversible within 60 min. Transcainide had little effect on the k-1 of [3H]batrachotoxinin even at concentrations 1000-fold greater than its IC50, indicating a low affinity of Transcainide for activated channels. However, Transcainidee decreased the k + 1 of [3H]batrachotoxinin at a concentration very close to its IC50 concentration for inhibiting equilibrium [3H] batrachotoxin binding. The results are discussed in terms of a model in which Transcainide inhibits [3H] batrachotoxin binding by binding specifically to and stabilizing a nonactivated state of the cardiac sodium channel.[1] Reduction of sodium current by Transcainide was concentration-dependent, with an ED50 of approximately 0.5 μM (n = 9).[2] |
Synonyms | R54718, R 54718, R-54718 |
Molecular Weight | 373.53 |
Formula | C22H35N3O2 |
CAS No. | 88296-62-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.74 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Transcainide 88296-62-2 Membrane transporter/Ion channel Sodium Channel R54718 R 54718 R-54718 inhibitor inhibit